Non-adherence rates to antiplatelet drugs in patients with acute myocardial infarction (AMI) range from 13% to 60%. We aimed to evaluate whether individual health education can improve adherence to treatment with clopidogrel in patients after AMI. This was a prospective, single-center, randomized clinical trial with a 12-month follow-up. Patients with AMI treated with percutaneous coronary intervention (PCI)
Introduction
Antiplatelet therapy is the cornerstone of the treatment in patients with acute coronary syndrome (ACS). Pharmacodynamic response to clopidogrel shows substantial interpatient variability. Patients with coronary artery disease (CAD) and lesser platelet inhibition in response to clopidogrel appear to be at increased risk for cardiovascular events [1, 2] . Low adherence to treatment is probably the major cause of clopidogrel "resistance" [3] [4] [5] . Despite the importance of secondary prevention, non-adherence rates to prescribed, evidence-based medicines for patients with acute myocardial infarction (AMI) range from 13% to 60% [6] . Moussa and Colombo [7] highlighted the necessity of patients' education regarding the risks and benefits of dual antiplatelet treatment to avoid premature discontinuation of the drug. Nevertheless, no standard approach has yet been developed.
The aim of this study was to evaluate whether individual health education can improve adherence to treatment with clopidogrel leading to more efficient inhibition of the P2Y12 receptor in patients after AMI.
Methods

Study population and recruitment
This prospective, single-center, randomized clinical trial with a 12-month follow-up was conducted at Antoni Jurasz University Hospital (Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland). The recruitment phase of the study was from 1st October 2010 until 31st October 2011. All patients with AMI (both ST-elevation MI and non-ST elevation MI) and treated with percutaneous coronary intervention (PCI) were screened for eligibility. The exclusion criteria were defined as follows: the need for prolonged use of heparin or fondaparinux, oral anticoagulant therapy, bleeding disorders (including thrombocytopenia < 100 × 10 3 /µL), anemia (HGB < 10.0 g/dL), active inflammation, heart failure in NYHA class III and IV, and life expectancy < 1 year.
Two hundred patients, who gave informed written consent, were randomly assigned 1:1 to receive additional individual educational intervention (EI) or standard treatment (ST). Nine patients withdrew their consent during follow-up (all from the ST group), thus the study population comprised of 191 patients, for whom the follow-up data were available. The study population characteristics are shown in Table 1 .
In-hospital management and discharge treatment recommendations strictly adhered to the European Society of Cardiology guidelines. Patients received a 600 mg loading dose and a 75 mg maintenance dose of clopidogrel in combination with aspirin doses of 300 mg and 75 mg, respectively. To avoid additional confounding factors, concomitant therapy was standardized and included bisoprolol, perindopril and simvastatin, if no contraindications were present. Before being discharged from the hospital all patients obtained information regarding the need for systematic intake of the prescribed drugs as well as the hazards associated with its premature termination. Additionally, they were provided with a written warning, enclosed in the discharge letter, that read: "Do not stop treatment prematurely! Earlier discontinuation of the treatment may result in stent thrombosis and sudden cardiac death!". Follow-up visits were scheduled at 3, 6, and 9 months after discharge. During every visit ADP-induced platelet aggregation (ADP-PA) and vasodilator-stimulated phosphoprotein phosphorylation (VASP) were assessed. Moreover, patients were asked to declare their adherence to the prescribed clopidogrel (systematic drug intake: YES or NO). Patients assigned to the EI group were scheduled for additional educational meetings with the attending physician at the end of hospitalization and at every follow-up visit. The intent of the meetings was to explain the pathophysiology and symptoms of CAD, to elucidate goals and potential gain of the treatment, and to highlight the risk of premature termination of antiplatelet therapy.
Patients' adherence to the medication regimen was also verified based on the data from The National Health Fund regarding prescribed drugs purchase. Adherence was defined as the proportion of drug availability (the number of purchased clopidogrel tablets) to drug requirement (the number of clopidogrel tablets needed to complete the treatment = the number of follow-up days) and was arbitrarily judged as adequate when the proportion exceeded 80%.
The primary endpoint
The primary endpoint was defined as non-adherence to clopidogrel during follow-up (drug availability ≤ 80%).
Secondary endpoints
Secondary endpoints included platelet function assessment (ADP-PA, VASP), adverse cardiovascular (CV) events (CV death, PCI for ACS, unscheduled CV hospitalization, combined of any adverse CV event).
The study protocol has been approved by The Ethical Committee of the Nicolaus Copernicus University.
Platelet function assessment
The ADP-PA examination was performed using impedance aggregometry. Whole blood was tested using a Multiplate Analyzer (Medical Cyclotron, Munich, Germany). The platelet aggregation rate was assessed as the area under the curve of the aggregation curve (AUC) and was expressed in units of aggregation (U). 
Statistical analysis
According to the Shapiro-Wilk test, the investigated continuous variables were non-normally distributed, therefore, they were reported as medians and interquartile ranges (IR). For comparisons between two and three groups, the Mann-Whitney unpaired rank sum test and the Kruskal-Wallis one-way analysis of variance were used, respectively. Categorical variables were expressed as a number of patients presenting the given feature and a percentage of patients in the analysed group. Categorical variables were compared using the c 2 test with the Yates' cor- STEMI -ST-elevation myocardial infarction; CAD -coronary artery disease; MI -myocardial infarction; PCI -percutaneous coronary intervention; CABG -coronary artery bypass grafting; CHF -congestive heart failure; BMI -body mass index; TC -total cholesterol; LDL-C -low-density lipoprotein -cholesterol; LDL -low-density lipoprotein; HDL-C -high-density lipoprotein-cholesterol; Tg -triglycerides; HbA 1c -glycated haemoglobin; WBC -white blood cells; RBC -red blood cells; HGB -haemoglobin concentration; HCT -haematocrit; PLT -platelets; MPV -mean platelet volume; BNP -brain natriuretic peptide; hsCRP -high sensitivity C-reactive protein 
Results
Patients assigned to the EI and ST groups did not differ significantly, with the exception of the prevalence of diabetes mellitus and glucose concentration on admission (Tab. 1). The evaluation of the patients' adherence to treatment with clopidogrel based on the data from The National Health Fund did not differ significantly between both groups of patients (Tab. 2). However, the prevalence of non-adherence defined as the drug availability (≤ 80%) tended to be higher in EI patients when compared with ST group (49% v. 38.5%; p = 0.13). Interestingly, self reported proportion of adherence to treatment (declaration of systematic clopidogrel intake at each follow-up visit) was clearly distinct and amounted to 92% and 95.5%, respectively. No difference between EI and ST patients regarding platelet function parameters reflecting inhibition of P2Y12 receptor was found. With regard to the clinical outcome, unexpected but substantial differences in the prevalence of unscheduled CV hospitalizations appeared. The rate of CV death as well as ACS treated with PCI during follow-up was very low and did not differ between groups. According to multivariate analysis, female gender was the only predictor of adherence to antiplatelet treatment OR 2.504 (95% CI 1.254-4.999, p = 0.009).
Discussion
"Drugs don't work in patients who don't take them" -C. Everett Koop, MD. Medication adherence is an issue of growing concern for those working to improve health system performance. Promoting adherence to medications offers a rare opportunity to simultaneously improve health outcomes whilst reducing costs in patients after AMI [8, 9] . On the basis of our previous experience [10] [11] [12] , we assumed that individual, complex health education which would begin with hospitalization and continue during follow-up shall result in the improvement of patients' adherence to the treatment with clopidogrel in patients after AMI. Our health education intervention aimed to explain pathophysiology and symptoms of coronary artery disease, to elucidate goals and potential gain of the treatment and to highlight the risk of premature termination of antiplatelet therapy. However, we failed to demonstrate any benefits of this health education intervention.
Ferreira-González et al. [13] related 10.6% of non-adherence to dual antiplatelet treatment in 1,622 consecutive patients undergoing drug eluting stent (DES) implantation. However, these findings were based on patient declarations and were not verified by prescription refill control. They concluded that antiplatelet therapy discontinuation after DES implantation is not exceptional, it is usually temporary and does not appear to have a large impact on the risk [13] . Furthermore, taking into account the considerable differences between self-reported and verified data regarding prescribed drugs purchase revealed in our study, we can doubt the veracity of these results. The Myocardial Ischaemia National Audit Project Registry and the General Practice Research Database revealed that out of the 7543 patients after AMI only 68.6% with non-STsegment elevation myocardial infarction (NSTEMI) and 62.8% with ST-segment elevation myocardial infarction (STEMI) received a clopidogrel prescription in the first 3 months after discharge from the hospital. The adjusted odds of prescribed clopidogrel at 12 months were similar after NSTEMI 53% (95% CI 51-55) and STEMI 54% (95% CI 52-56) [14] . This data corresponds with ours and likely reflects true adherence.
Several studies have tried to identify patients who fail to follow medical advice on discharge from hospital. This knowledge may help the health care professionals to develop quality improvement initiatives which target this high-risk population in order to improve their outcomes following AMI [15] . In our study, male gender was associated with significantly lower adherence as compared with female gender.
Melloni et al. [16] evaluated adherence to medication by means of interviewing 1,077 patients after acute coronary syndromes (ACS). At 3-month follow-up, 304 patients (28.2%) had discontinued at least one of the prescribed medicines. Most cases of drug discontinuation (61.5%) were self-determined. The factors independently associated with self-discontinuation included: having no or limited healthcare cover, increasing the number of medications, not using reminder tools (e.g., pillbox), lower education status, and dialysis [16] . On the basis of patient interviews Garavalia et al. [6] defined reasons for non-adherence to prescribed medication in patients after AMI. Adverse effects that were painful and interfered with daily life constituted the most common reason for discontinuing the use of medication.. Less common reasons for discontinuation were: prescription confusion, cost, distrust in medicine, healthcare system, and preference for alternative therapies. Reasons for clopidogrel discontinuation were duration confusion, adverse effects and cost [6] . According to Muntner et al. [17] , the risk for low clopidogrel adherence was higher in patients who reported, prior to PCI, taking smaller doses of medication due to cost or had difficulty filling prescriptions, had difficulty reaching their primary physician, or were uncomfortable asking their doctor for advice. Sengstock et al. [18] highlighted the need for corrective measures to commence on hospitalization and involve practitioners who can follow patients after discharge. A solid, ongoing relationship between patients, their primary-care physicians and cardiologists is essential regarding this issue [18] . Taking into account the findings from the previous studies, we continue with the evidence-based treatment initiated in the hospital [10] [11] [12] 19] . To build mutual trust, every patient was accompanied by the same physician during hospitalization and follow-up. Nevertheless, our educational intervention failed.
Ho et al. [20] tested the impact of multifaceted intervention and usual care on adherence to medication regimens in 253 patients with ACS. The intervention lasted for 1 year following discharge and comprised pharmacist-led medication, patient education, collaborative care between pharmacist and patient's primary care clinician and/or cardiologist, and 2 types of voice messaging (both educational and medication refill reminder calls). Using the same definition of primary endpoint that we used, a greater proportion of intervention patients adhered to clopidogrel, statins and ACEI/ARB but not b-blockers. However, this did not lead to any differences in the proportion of patients who achieved blood pressure and LDL-cholesterol level goals [20] . McDonald et al. [21] performed a systematic review of the published randomized controlled trials (RCTs) of interventions aimed at assisting patients' adherence to prescribed medications. Interestingly, 49% of the interventions tested (19 out of 39 in 33 studies) were associated with statistically significant increases in medication adherence and only 17 reported statistically significant improvements in the treatment outcomes. Almost all the interventions that were effective for long-term care were complex, and included combinations of more convenient care, information, counseling, reminders, self-monitoring, reinforcement, family therapy and other forms of additional supervision or attention. Even the most effective interventions had modest effects [21] .
However, the current analysis has potential limitations. Firstly, this was a single-center study and the population was relatively small. Therefore, our findings are uncertain and cannot be generalized. Secondly, drug availability does not necessarily reflect its actual intake. This, however, is a methodological limitation that should be taken into account when using this particular approach for evaluation of adherence to medication.
Conclusions
In conclusion, the program of individual health education did not improve adherence to treatment with clopidogrel. The expected benefits of medications are not available at currently achievable levels of adherence. There is a need for further innovative approaches to assist patients to follow prescribed medications in order to improve health outcomes after AMI. The self-reported adherence assessment is unreliable and cannot be used for effective treatment guidance.
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